HERVolution Therapeutics: Detailed Company Information & Corporate Profile
Contact top employees from
HERVolution Therapeutics
Summary
The business currently specializes in Biotechnology area. The company has 10-50 employees. Register with SignalHire to connect with HERVolution Therapeutics employees and management.
| HERVolution Therapeutics Website | hervolutiontx.com |
| Industries | |
| HERVolution Therapeutics Headquarters address | Nordre Fasanvej 215, Frederiksberg, Capital Region of Denmark, 2000 DK |
| Company Size | 10-50 employees |
| Specialties | Oncology, Aging, Dark Genome, ALS, Diabetes, Longevity, Senescense |
| Founded | 2018 |
| Estimated Annual Revenue | $10M - 50M |
| Updated: | 2026-07-27 |
Workforce Turnover
Length of Employment
HERVolution Therapeutics's workforce includes employees across a wide range of tenure levels.
33% have been with the company for 1 to 2 years33% have been with the company for 3 to 4 years17% have been with the company for 5 to 7 years17% have been with the company for more than 11 yearsContact top employees from
HERVolution Therapeutics
J Robert ColemanChairman and CEO
Lilli BourkeProject Consultant
Companies Similar to HERVolution Therapeutics
HERVolution Therapeutics Corporate Information: FAQ
HERVolution Therapeutics operates in the Biotech industries. More details can be found on the official website: hervolutiontx.com.
HERVolution Therapeutics has offices located in Frederiksberg, DK.
The headquarters of HERVolution Therapeutics are located in Frederiksberg, Denmark.
HERVolution Therapeutics currently employs 10-50 people.
Data Privacy
GDPR COMPLIANT
SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.
CCPA COMPLIANT
SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.
